Chest:心率可能是肺栓塞患者预后因素

2021-09-05 MedSci原创 MedSci原创

肺栓塞患者入院心率与30天全因死亡率和肺栓塞相关死亡率呈正相关。

识别低风险肺栓塞患者的临床预后评分(简化肺栓塞严重程度指数(sPESI))和识别中高风险肺栓塞患者(Bova评分)均将心率作为预后指标。然而,心率与肺栓塞结局之间的相关性仍不清楚,对肺栓塞患者进行危险分层的最佳心率临界值尚不明确。 近期发表在CHEST杂志的一项研究探索了心率与肺栓塞结局之间的相关性。 研究纳入2001年至2021年44331例合并非低血压(收缩压>90 mmHg)的肺栓塞患者,主要结局包括30天全因死亡率和肺栓塞死亡率。研究使用层次回归分析评估患者入院心率与肺栓塞结局之间的相关性。 结果表明,肺栓塞患者入院心率与30天全因死亡率和肺栓塞死亡率呈正相关。 以心率80-99次/分钟的患者为对照,心率较快患者的30天全因死亡率较高(心率 100-109次/分钟, OR=1.5; 心率 110-119次/分钟, OR=1.7; 心率 120-139次/分钟, OR=1.9; 心率 > 140次/分钟, OR=2.4)。心率较慢患者的30天全因死亡率显著低于对照组(心率 60-79 次/分钟, OR=0.6; 心率 < 60次/分钟, OR= 0.5)。同样,

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929667, encodeId=153e192966ed3, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jan 16 04:19:49 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051687, encodeId=e097205168e58, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 27 03:19:49 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692222, encodeId=49761692222cc, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 07 17:19:49 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014715, encodeId=dc3c1014e15e9, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:24:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479308, encodeId=f64814e9308e0, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sun Sep 05 04:19:49 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014536, encodeId=a3f2101453606, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Sep 04 14:00:31 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2022-01-16 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929667, encodeId=153e192966ed3, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jan 16 04:19:49 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051687, encodeId=e097205168e58, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 27 03:19:49 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692222, encodeId=49761692222cc, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 07 17:19:49 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014715, encodeId=dc3c1014e15e9, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:24:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479308, encodeId=f64814e9308e0, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sun Sep 05 04:19:49 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014536, encodeId=a3f2101453606, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Sep 04 14:00:31 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929667, encodeId=153e192966ed3, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jan 16 04:19:49 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051687, encodeId=e097205168e58, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 27 03:19:49 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692222, encodeId=49761692222cc, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 07 17:19:49 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014715, encodeId=dc3c1014e15e9, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:24:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479308, encodeId=f64814e9308e0, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sun Sep 05 04:19:49 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014536, encodeId=a3f2101453606, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Sep 04 14:00:31 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929667, encodeId=153e192966ed3, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jan 16 04:19:49 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051687, encodeId=e097205168e58, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 27 03:19:49 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692222, encodeId=49761692222cc, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 07 17:19:49 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014715, encodeId=dc3c1014e15e9, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:24:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479308, encodeId=f64814e9308e0, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sun Sep 05 04:19:49 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014536, encodeId=a3f2101453606, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Sep 04 14:00:31 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2021-09-05 pyunzhen

    学习到了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1929667, encodeId=153e192966ed3, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jan 16 04:19:49 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051687, encodeId=e097205168e58, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 27 03:19:49 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692222, encodeId=49761692222cc, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 07 17:19:49 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014715, encodeId=dc3c1014e15e9, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:24:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479308, encodeId=f64814e9308e0, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sun Sep 05 04:19:49 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014536, encodeId=a3f2101453606, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Sep 04 14:00:31 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1929667, encodeId=153e192966ed3, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Jan 16 04:19:49 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051687, encodeId=e097205168e58, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Mar 27 03:19:49 CST 2022, time=2022-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692222, encodeId=49761692222cc, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 07 17:19:49 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014715, encodeId=dc3c1014e15e9, content=学习到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 09:24:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479308, encodeId=f64814e9308e0, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sun Sep 05 04:19:49 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014536, encodeId=a3f2101453606, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Sep 04 14:00:31 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2021-09-04 仁术2021

    不错,学习了

    0

相关资讯

Eur Heart J:低死亡风险的肺栓塞患者右心室评估的临床意义

通过超声心动图、计算机断层扫描或BNP/NT-proBNP和肌钙蛋白水平升高评估的RVD与低风险急性PE患者的短期死亡相关。

J Thromb Haemost:癌症患者尸检时肺栓塞情况

在癌症患者尸检时,PE的比例是相当大的。虽然研究人群不能代表总体癌症人群,但这表明PE是癌症患者重要的并发症。

Lancet respir med:北美地区肺栓塞有关的死亡率变化趋势研究

总体上,北美肺栓塞有关的死亡率呈现下降趋势,加拿大达到一个平稳期,而在美国,年轻人和中年人中观察到了死亡率反弹增长。这一现象与其他心血管疾病死亡率的上升趋势相似,反映出美国民众危险因素暴露和医疗保健获

Eur Radiol: 双能CTA灌注缺损表现是否可提示肺栓塞患者预后不良?

双能CTA (DECTA)可以根据物质能量吸收的特征提示物质的组成,并已被用于检测PE。DECTA可以在不增加辐射剂量的情况下同时评估肺血管和实质内碘的分布。

JAMA Cardiol:4级肺栓塞临床概率评分(4PEPS)在减少肺栓塞过度影像学检查方面的应用

在减少影像学检查方面,4PEPS策略比之前提出的所有策略表现更好。